Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41

Benzinga · 4d ago
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.